Physician Related Diagnostic Delay And Demographic And Clinical Differences Between Patients With Ankylosing Spondylitis And Non-Radiographic Axial Spondyloarthritis

Firdevs ULUTAŞ
Veli ÇOBANKARA
Uğur KARASU
Serdar KAYMAZ
Canan YAŞAR
Department of Rheumatology, Internal Medicine, Pamukkale University, Denizli, Turkey

Umut KALYONCU
Department of Rheumatology, Internal Medicine, Hacettepe University, Ankara, Turkey

Hande ŞENOL
Department of Biostatistics, Pamukkale University, Denizli, Turkey

Abstract:
Aim: Axial spondyloarthritis (axSpA) is a common chronic inflammatory disease. A large number of comparison studies have been conducted for ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) including disease burden, treatment modalities and patient characteristics. The aim of this study was to compare physician related diagnostic delay time between patients with AS and nr-axSpA.

Method: In our retrospective study we included 266 patients with axSpA. Patients were classified into two subgroups as AS and nr-axSpA. The time from back pain onset until the diagnosis of axSpA was defined as the diagnostic delay. The first specialist referred to and the first diagnosis for each patient were noted in detail. Patient characteristics, clinical manifestations, laboratory and imaging results at diagnosis were also compared between subgroups. Analyses of the study were performed with SPSS and statistical significance was determined as p:0.05.

Results: The diagnostic delay time was significantly longer for AS patients [6 ± 8.14 years, 1.62 ± 2.54 years]. When the first specialists were evaluated, 40.9% of all patients were initially consulted by physical therapy and rehabilitation followed by 29.7% neurosurgery, 19.9% rheumatology. The most common diagnosis was fibromyalgia 52.6% (140) among all of the patients followed by ankylosing spondylitis 28.9% (77), lumbar disc hernia 12.7% (34).

Conclusion: The vast majority of patients were initially evaluated by healthcare providers other than rheumatologists and mostly diagnosed with fibromyalgia. Efforts to increase awareness and to educate first healthcare providers may shorten the diagnostic delay time.

Keywords: ankylosing spondylitis, non-radiographic axial spondyloarthritis, diagnostic delay, rheumatologists, physical therapy and rehabilitation specialists

I. INTRODUCTION
Axial spondyloarthritis (axSpA) is a common chronic inflammatory rheumatologic disease. Inflammatory back pain is the most common symptom that occurs before 45 years of age and for more than 3 months. AxSpA primarily affects the spine and/or sacroiliac joints (SIJs) [1]. From the results of numerous community-based studies, the prevalence of axSpA is around 1% of the population [2]. Patients with axSpA are identified as ankylosing spondylitis (AS) or non-radiographic
axial spondyloarthritis (nr-axSpA), distinguished by the presence or absence of definitive sacroiliitis on plain radiographs [3].

Delayed diagnosis and inadequate treatment lead to structural damage, irreversible loss of spinal mobility and poor quality of life in patients with axSpA [4]. 5-10% of nr-axSpA patients have been shown to develop AS within 2 years and 20% of them within 5 years [5]. It was also shown that the progression occurs more frequently in male patients with active sacroiliitis, positive HLA B-27 and high c-reactive protein (CRP) values at diagnosis [6]. Currently, it is thought that AS and nr-axSpA are two different clinical entities in the same spectrum, only differing in terms of chronicity [7]. Therefore, for early diagnosis and timely treatment, it is very important to know the similarities and differences between these two clinical entities.

Recently, many studies have compared patients with AS and nr-axSpA in terms of patient characteristics, disease burden, activity criteria and treatment modalities. The aim of this study was to compare diagnostic delay time, physician related factors (specialists consulted initially and first diagnoses) in addition to all of the above parameters between patients with AS and nr-axSpA.

II. METHOD

A. PATIENT SELECTION AND DEFINITION OF AXIAL SPONDYLOARTHRITIS

We evaluated retrospectively the medical records of 360 patients in total between December 2019 and January 2020. Overall, 94 of them were excluded due to insufficient data and irregular follow-up and, included 266 patients diagnosed with axSpA up to November 2019. All of them were diagnosed with axSpA in our tertiary single center and followed up regularly up to the present in the rheumatology department of internal medicine at Pamukkale University, Denizli. The patients that were diagnosed with axSpA earlier before came to our centre were excluded.

All of the patients fulfilled the 2009 axSpA classification criteria of the Assessment of SpondyloArthritis International Society (ASAS) [8]. All of them had inflammatory back pain initially. SIJ x-rays were present for all axSpA cases. All of the patients with axSpA are classified into two subgroups as AS and nr-axSpA, distinguished by the presence or absence of definitive sacroiliitis and structural damage on the baseline plain radiographs. All of the AS cases were diagnosed based upon the presence of radiographic sacroiliitis on imaging modalities regardless presence of HLA B-27. Patients with nr-axSpA that had no SIJ changes on plain x-rays have been underwent to MRI imaging. Only two patients in nr-axSpA group were diagnosed without imaging, with HLA B-27 positivity. All of the pelvic X-ray and MRI scans of the sacroiliac joints were evaluated by the same rheumatologist who was blinded to the laboratory results and clinical presentations. Hip involvement of all patients was noted as current or ever by the same rheumatologist. Also, MRI findings of sacroiliac joints (SIJs) were grouped as subchondral bone marrow edema and/or degenerative fatty changes.

B. DEFINITION OF DISEASE DURATION AND DELAY OF DIAGNOSIS

The first specialist who evaluated the patient and the first diagnosis for each patient before the correct diagnosis were noted. The information notes containing detailed anamnesis and physical examination for each patient were examined in detail. The time from diagnosis to the present was defined as the disease duration. The time from back pain onset until diagnosis of axSpA was defined as the diagnostic delay.

C. OUTCOME MEASURES

Patient characteristics (gender, age, disease duration, diagnostic delay, specialists initially referred to and first diagnoses), clinical manifestations, laboratory results [c-reactive protein (CRP), erythrocyte sedimentation rate (ESR)] and imaging results [X-ray, magnetic resonance imaging (MRI)], Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores at diagnosis and treatment modalities were analyzed retrospectively and compared between the two subgroups of including AS and nr-axSpA.

All of the patients presented with inflammatory back pain (IBP) initially. Other extra-articular manifestations including uveitis, inflammatory bowel disease and peripheral arthritis were defined as present or not present at follow-up. Information on medication use and drugs in the follow up to present were collected from prescriptions in the medical charts. Human Leukocyte Antigen B-27 (HLA B-27) status was noted as positive, negative and not available.

D. STATISTICAL ANALYSIS

The medical records of all patients were obtained using the Probel data system. Analyses of the study were performed with SPSS (IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version25.0, Armonk, NY: IBM Corp.), and statistical significance was determined as p:0.05. In the study, the suitability of continuous variables to normal distribution was examined by Shapiro-Wilk and Kolmogorov Smirnov Tests. Continuous variables were expressed as mean ± Standard deviation, median (Interquartile range – IQR) and categorical variables were expressed as number and percents. For independent groups comparisons Mann-Whitney U test were used because of parametric test assumptions were not provided. Differences between categorical variables were made using chi-square test.

III. RESULTS

Overall 266 axSpA patients (60% male) were classified into two subgroups, including 213 (80.1%) patients with AS and 53 (19.9%) patients with nr-axSpA. 143 (67.1%) patients in the AS group and 18 (33.9%) patients in the nr-axSpA group were male [p:0.0001], table 1. The mean age of patients was 44 (23-77) in the AS group and 37 (18-58) in the nr-
axSpA group. In patients with AS compared to nr-axSpA, longer disease duration [10.55 ± 9.68; 3.61 ± 3.67; p:0.0001] was also seen (Table 1). At diagnosis, higher ESR values [29.63 ± 16.44; 23.17 ± 12.59; p:0.011], higher CRP values [1.34 ± 1.57; 0.66 ± 0.67; p:0.004] and higher BASDAI scores [4.49 ± 2.52; 3.08 ± 1.4; p:0.002] were seen in the AS group compared to the nr-axSpA group.

Table 1: Comparison of different parameters between AS and nr-axSpA subgroups

Until the correct diagnosis, the mean number of specialists who evaluated the patients was 2 and 1 in AS and nr-axSpA groups, respectively [p:0.105]. Among 266 patients with axSpA, the mean diagnostic delay time was significantly longer in AS patients compared with nr-axSpA patients, respectively [6 ± 8.14 (year); 1.62 ± 2.54 (year); p:0.0001].

Patients were firstly evaluated by physician of physical therapy and rehabilitation 109 (40.9%), surgeons 89 (33.4%) (79 neurosurgeries, 10 orthopedics), rheumatologists 53 (19.9%), and others 15 (5.6%) (13 internal medicine physicians, 2 general practitioners). Physicians of physical therapy and rehabilitation were more frequently seen nr-axSpA patients than AS patients [52.8% (28), 38% (81), p:0.079]. The most common initial diagnosis was fibromyalgia 140 (52.6%), followed by axSpA 77 (28.9%), lumbar disc hernia 34 (12.7%), non-specific low back pain 12 (4.5%), osteoarthritis 3 (1.1%). According to first diagnosis, accuracy of axSpA diagnosis was more prominent in nr-axSpA group than AS (60.3% vs 21.1%, p:0.005). On contrary, first diagnosis of fibromyalgia were more frequent in the AS group than nr-axSpA (61.0% vs 18.8%, p:0.005). Accuracy of axSpA diagnosis was higher in rheumatologist than physician of physical therapy and rehabilitation and surgeons, 83.0%, 23.8%, 6.7%, respectively (Table 2).

Table 2: The first diagnoses and physicians among all of the patients (n)

IV. DISCUSSION

Chronic back pain is commonly seen, about 13% of adults in the general population, and axSpA accounts for only 5% of cases [9]. Lack of validated diagnostic criteria, reliable biomarkers and limitations on physical examination of the back and SIJs lead to late recognition of axSpA. Additional important reasons for the diagnostic delay are physician related, referral delay time and incorrect diagnoses. In a community wide epidemiologic study it was shown that many patients with axSpA were referred to specialties other than...
rheumatologists, such as orthopedics, spine surgeons and rehabilitation medicine via primary care doctors [10]. Deodhar A. et al has stated that only 37% of patients with AS are diagnosed by rheumatologists, the remaining 63% are diagnosed by primary care (26%), physical therapy (7%), orthopedic surgery (4%) and pain clinics (4%) and the estimated diagnostic delay for axSpA is 14 years [11]. Vedat G et al. stated that the diagnostic delay was 8.1 years among 393 patients with AS. Lumbar disc hernia (LDH) was the most reported initial diagnosis for about 33% of patients and prior diagnosis of LDH was a predictive factor for diagnostic delay [12]. As a result, many patients with axSpA are initially evaluated by healthcare providers other than rheumatologists. Other specialists may not be aware of the prevalence and importance of axSpA and may be unfamiliar with presentations of the disease. In our study we found that the vast majority of patients were first evaluated by specialists of physical therapy and rehabilitation (FTR) and surgeons before specialists of rheumatology, and the most common initial diagnosis was fibromyalgia, accounting for 52.6% of all patients. We thought that these two situations ultimately cause to referral and diagnostic delay.

Although the majority of patients in both groups were evaluated by FTR specialists initially, more than half of the patients in the nr-axSpA group were diagnosed with axSpA at first admission because MRI scans were performed for the vast majority of patients (96.2%) in this group. We thought that the presence of active sacroiliitis on MRI contributes greatly to the early diagnosis and abbreviates the diagnostic delay time in patients presenting with appropriate clinical symptoms. But it should be kept in mind that subchondral bone marrow edema on MRI is not a specific evidence for axSpA since it can be seen in 23% of those with mechanical low back pain, and in 7% of healthy volunteers [13]. Mild inflammatory changes may be seen also in healthy athletes. Today, although MRI is the most sensitive imaging determinant, another important point is that positive MRI findings alone can result in over diagnosis of axSpA [14]. Because of the high cost, sacroiliitis on MRI should not be an entry screening method. Especially for appropriate, selected patients presenting with inflammatory back pain and without findings of sacroiliitis on plain x-rays as in our study, many of them may be diagnosed at an early, non-radiographically state of disease using combined MRI and ASAS criteria [15].

In a cohort study involving 755 axSpA patients, the AS group showed male dominance, higher mean age, higher inflammatory markers and more frequent radiographic damage compared to nr-axSpA [16]. Also Clementina Medina et al. reported longer disease duration, longer time to diagnosis, high CRP levels and high BASDAI values are more common in AS patients compared to nr-axSpA, and each poses a risk of structural damage [17]. All of the above findings correlated with the findings of our study. Extra-articular manifestations occur in 25-35% of axSpA patients [18]. In our study there was no significant difference between the two subgroups in terms of the frequency of peripheral arthritis and inflammatory bowel disease, but the frequency of uveitis [7.9%, 0%; p:0.028] was significantly higher in patients with AS than the nr-axSpA group. This condition may be related to longer disease duration. Hip involvement has been demonstrated in 25-35% of patients with AS, associated with greater functional limitation and worse prognosis, but has not been studied in nr-axSpA patients. It has been reported that it is more common in patients with early onset AS, and with axial and enthesal disease [19]. In our study, hip involvement was detected in 13.2% of patients with AS, but was not detected in the nr-axSpA group [13.2%, 0%; p:0.005]. Positive HLA B-27 and high CRP are the most commonly used laboratory biomarkers for axSpA. HLA B-27 positivity in nr-axSpA and AS groups was 77% and 78%, respectively [20]. Imke Redeker et al. stated that among 1677 patients with axSpA, the mean diagnostic delay was 5.7 years; HLA B-27 negativity is a risk factor for longer diagnostic delay time [21]. In our study HLA B-27 was not studied in one third of AS patients. Also, this condition may be one of the causative factors for diagnostic delay. It was stated that both AS and nr-axSpA had comparable burden of disease and treatment modalities [22]. But the result drawn from our study is that use of anti-tumor necrosis factor (anti-TNF) agents was significantly higher in patients with AS, whereas NSAIDs were sufficient for approximately half of patients in the nr-axSpA group.

Various referral strategies have been developed for early diagnosis. The vast majority of them include one or more typical spondyloarthritides features in addition to inflammatory back pain for>3 months and age of onset<45 as entry criteria. Using these candidate parameters, about 35-45% of patients were early diagnosed with axSpA [23]. In a PROSPa study, 751 patients had inflammatory back pain (IBP) beginning at an age of <45 years. The presence of 1 of 3 criteria, including HLA B-27 positivity, current IBP, and MRI evidence is effective for early diagnosis in 46% of patients with axSpA [24]. A combination of AWARE criteria indicative for IBP and positive imaging or HLA B-27 positivity also benefits in the early detection of patients with axSpA [25]. ASAS and Brandt I strategies are the most sensitive (98%) but have low specificity (18% and 11% respectively). According to Brandt I strategies, patients are referred to a rheumatologist if HLA B-27 positivity and/or IBP is present [26]. The conclusion drawn from the above studies is that inflammatory back pain is the most important entry criteria for referral. Although all of the patients in our study had inflammatory back pain initially, more than half of them were considered such as fibromyalgia. So the differences between inflammatory and mechanical back pain should be explained exactly to health care professionals who first meet patients. HLA B-27 positivity, positive MR imaging likewise in our study, extra-articular clinical manifestations may have contributory effect in referring patients to appropriate specialists. Patients with acute anterior uveitis, inflammatory bowel disease and psoriasis may be target populations [27]. Therefore, specialists including ophthalmologists, gastroenterologists and dermatologists who manage extra-articular manifestations of axSpA may be good sources for patient referral. Also as in our study, it is also shown that women may develop nr-axSpA with the same frequency as men.

Our study has a few limitations that should be noted. One of the major limitations is that it is a retrospective study. The other limitation of our study is related to patient groups. The sample size in nr-axSpA group was small and the patient groups were non-homogeneous especially for HLA B-27.
Another point is that although the same rheumatologist analyzed the whole files of each patient including anamnesis, physical examination notes, imaging and laboratory results, all of the patients initially were evaluated by different rheumatologists at their outpatient visits. Today it is well known that early diagnosis and timely treatment improve symptoms and function among young adults with axSpA. As a result of diagnostic delay, patients more commonly experience functional limitations and disability. We must work to increase awareness among non-rheumatologist healthcare providers. Therefore, education of referring providers is very important. Also, validated referral strategies are necessary for selected patients in our country.

V. CONCLUSION

The vast majority of patients were initially evaluated by healthcare providers other than rheumatologists and mostly diagnosed with fibromyalgia. Efforts to increase awareness and to educate first healthcare providers may shorten the diagnostic delay time.

REFERENCES


